文献速递胃肠动力与功能性疾病

5-HT4受体激动剂Minesapride治疗便秘型肠易激综合征的随机对照试验

Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-03-14

该双盲2期试验纳入171例罗马III标准便秘型肠易激综合征(IBS-C)日本患者,随机接受Minesapride(1、4、12或40 mg)或安慰剂每日一次共4周。

要点

  • Minesapride 40 mg每日一次可改善IBS-C患者每周CSBM频率。
  • 12 mg和40 mg组整体IBS严重度指数评分较安慰剂显著下降。
  • 不良事件发生率与安慰剂相近,最常见为腹泻。

核心结论

  • 在日本IBS-C患者中,Minesapride增加排便频率、减轻腹部及整体IBS-C症状且耐受性良好。

研究设计与样本

  • 双盲2期随机对照试验,纳入171例罗马III标准IBS-C患者,来自日本33个中心,2012年12月至2013年8月。
  • 患者随机接受Minesapride 1、4、12或40 mg或安慰剂每日一次,共4周。

主要发现

  • 40 mg组腹部症状评分改善。
  • 治疗中出现的不良事件比例在Minesapride汇总组和安慰剂组分别为55.0%和60.0%。
  • 最常见治疗中出现的不良事件为腹泻,在Minesapride汇总组和安慰剂组分别为42.9%和37.1%。

临床怎么用

  • 对于IBS-C患者,Minesapride 40 mg每日一次可能改善排便频率和整体症状,但需关注腹泻风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment options for irritable bowel syndrome with constipation (IBS-C) are limited-new prokinetic drugs are needed. We evaluated the efficacy and safety of minesapride (DSP-6952), a partial agonist with high affinity for 5-HT4 receptors, in patients with IBS-C in Japan. METHODS: We performed a double-blind phase 2 study of 171 patients with Rome III-defined IBS-C at 33 centers in Japan, from December 2012 through August 2013. Patients were randomly assigned to groups given minesapride (1, 4, 12, or 40 mg) or placebo once daily for 4 weeks. The primary outcome was efficacy, defined as improvement in the weekly frequency of complete spontaneous bowel movements (CSBMs), abdominal symptoms, and IBS-C symptoms (according to the Japanese version of the IBS severity index score). For evaluation of safety, adverse events (AEs) were recorded. RESULTS: The least squares mean change from baseline in the weekly frequency of CSBMs was greater in all minesapride groups than in the placebo group at week 4 (40 mg vs placebo, P = .040). The abdominal symptoms score improved in minesapride 40 mg group. The overall IBS severity index score decreased from baseline to week 4 in all treatment groups-especially in the 12 mg and 40 mg groups (P = .048 and <.001 vs placebo, respectively). The proportions of patients with treatment-emergent AEs in the pooled minesapride and placebo groups were 55.0% and 60.0%, respectively. The most common treatment-emergent AE was diarrhea (in 42.9% and 37.1% of patients in the pooled minesapride and placebo groups, respectively). CONCLUSIONS: In a phase 2 trial of patients with IBS-C in Japan, minesapride increased stool frequency (measured by CSBMs), reduced abdominal and overall IBS-C symptoms, and was well tolerated. Japan Pharmaceutical Information Center trial no: JapicCTI-122041.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Fukudo S, Nakamura M, Hamatani T, et al. Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2020. PMID: 32184185. doi:10.1016/j.cgh.2020.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。